Peptidergic Systems as Antitumor Targets: A Right Direction to Fight Cancer?-Reference-Cited by-同舟云学术

Peptidergic Systems as Antitumor Targets: A Right Direction to Fight Cancer?

Published:2023-10-13 Issue:20 Volume:15 Page:4975
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Rodríguez Francisco D.¹²^ORCID,Coveñas Rafael²³^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Biology, Faculty of Chemical Sciences, University of Salamanca, 37007 Salamanca, Spain

2. Group GIR-BMD (Bases Moleculares del Desarrollo), University of Salamanca, 37007 Salamanca, Spain

3. Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla y León (INCYL), University of Salamanca, 37007 Salamanca, Spain

Abstract

Undoubtedly, much progress has been made in treating cancer over the past few years, but unfortunately, 28 [...]

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/20/4975/pdf

Reference17 articles.

1. Global cáncer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Coveñas, R., and Muñoz, M. (2022). Involvement of the substance P/neurokinin-1 receptor system in cáncer. Cancers, 14.

3. Peptide-drug conjugates and their targets in advanced cancer therapies;Hoppenz;Front. Chem.,2020

4. Muñoz, M.F., Argüelles, S., Rosso, M., Medina, R., Coveñas, R., Ayala, A., and Muñoz, M. (2022). The neurokinin-1 receptor is essential for the viability of human glioma cells: A possible target for treating glioblastoma. BioMed Res. Int., 2022.

5. Sánchez, M.L., and Coveñas, R. (2022). The galaninergic system: A target for cancer treatment. Cancers, 14.